Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome

Fertility and Sterility

Volumn 94, Issue 5, 2010, Pages 1793-1798

  Fruzzetti, Franca ^a   Perini, Daria ^a   Lazzarini, Veronica ^a   Parrini, Donatella ^a   Gambacciani, Marco ^a   Genazzani, Andrea Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

cyproterone acetate; drospirenone; metformin; PCOS

Indexed keywords

CHOLESTEROL; CYPROTERONE ACETATE; DROSPIRENONE; ETHINYLESTRADIOL; GLUCOSE; INSULIN; LIPID; METFORMIN; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG; YASMINELLE; ANDROGEN; ANDROSTANE DERIVATIVE; ANTIDIABETIC AGENT; CYPROTERONE; ESTROGEN; MINERALOCORTICOID ANTAGONIST;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FEMALE INFERTILITY; GLUCOSE TOLERANCE; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERTENSION; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; ADOLESCENT; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DOSE RESPONSE; DRUG COMBINATION; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALDOSTERONE ANTAGONISTS; ANDROGENS; ANDROSTENES; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CYPROTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; METFORMIN; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; YOUNG ADULT; MINERALOCORTICOID RECEPTOR ANTAGONISTS;

EID: 77957196511     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.10.016     Document Type: Article

References (38)

1. D. Cibula, R. Cifkova, M. Fanta, R. Poledne, J. Zivny, and J. Skibova Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome Hum Reprod 15 2000 785 789
2. K. Berneis, M. Rizzo, V. Lazzarini, F. Fruzzetti, and E. Carmina Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome J Clin Endocrinol Metab 92 2007 186 189
3. B.O. Yildiz Haznedarolu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state J Clin Endocrinol Metab 87 2002 3871 3875
4. F. Carmassi, F. De Negri, R. Fioriti, A. De Giorgi, C. Giannarelli, and F. Fruzzetti Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome Thromb Res 116 2005 207 214
5. M. Kravariti, K.K. Naka, S.N. Kalantaridou, N. Kazakos, C.S. Katsouras, and A. Makrigiannakis Predictors of endothelial dysfunction in young women with polycystic ovary syndrome J Clin Endocrinol Metab 90 2005 5088 5095
6. S. Palomba, A. Falbo, F. Zullo, and F. Orio Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review Endocr Rev 30 2009 1 50
7. J.M. Lord, I.H. Flight, and R.J. Norman Metformin in polycystic ovary syndrome: systematic review and meta-analysis BMJ 327 2003 951 953
8. K.I. Cheang, and J.E. Nestler Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome? Reprod Biomed Online 8 2004 440 447
9. R. Pasquali, A. Gambineri, D. Biscotti, V. Vicennati, L. Gagliardi, and D. Colitta Effect of longterm treatment with metformin added to hypocaloric diet on body composition, fat distribution and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome J Clin Endocrinol Metab 85 2000 2767 2774
10. S. Tan, S. Hahn, S. Benson, T. Dietz, H. Lahner, and L.C. Moeller Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance Eur J Endocrinol 157 2007 669 676
11. K. Elter, G. Imir, and F. Durmusoglu Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study Hum Reprod 17 2002 1729 1737
12. L. Falsetti, and E. Galbignani Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome Contraception 42 1999 611 619
13. P.J. Hillard Oral contraceptives and the management of hyperandrogenism-polycystic ovary syndrome in adolescents Endocrinol Metab Clin North Am 34 2005 707 723
14. L. Morin-Papunen, I. Vauhkonen, R. Koivunen, A. Ruokonen, H. Martikainen, and J.S. Tapanainen Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study J Clin Endocrinol Metab 88 2003 148 156
15. J. Calaf, E. López, A. Millet, J. Alcañiz, A. Fortuny, and O. Vidal Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial J Clin Endocrinol Metab 92 2007 3446 3452
16. J.H. Barth, C.A. Cherry, F. Wojnarowska, and R.P.R. Dawber Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study Clin Endocrinol 35 1991 5 10
17. J. Hammerstein, J. Meckies, I. Leo-Rossberg, L. Moltz, and F. Zielske Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism J Steroid Biochem 6 1975 827 836
18. F. Lumachi, and R. Rondinone Use of cyproterone acetate, finasteride and spironolactone to treat idiopathic hirsutism Fertil Steril 79 2003 942 946
19. S. Nader, and E. Diamanti-Kandarakis Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis Hum Reprod 22 2007 317 322
20. R. Sitruk-Ware Pharmacological profile of progestins Maturitas 47 2004 277 283
21. B. Pehlivanov, and M. Mitkov Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome Eur J Contracept Reprod Health Care 12 2007 30 35
22. M. Guido, D. Romualdi, M. Giuliani, R. Suriano, L. Selvaggi, and R. Apa Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study J Clin Endocrinol Metab 89 2004 2817 2823
23. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome Fertil Steril 81 2004 19 25
24. J.K. Zawadski, and A. Dunaif Diagnostic criteria for polycystic ovary syndrome: towards a rational approach A. Dunaif, J.R. Givens, F. Haseltine, Polycystic ovary syndrome 1992 Blackwell Scientific Boston 377 384
25. R. De Pirro, F. Forte, A. Bertoli, A.V. Greco, and R. Lauro Changes in insulin receptors during oral contraception J Clin Endocrinol Metab 52 1981 29 33
26. J. Endrikat, C. Klipping, M. Cronin, C. Gerlinger, A. Ruebig, and W. Schmidt An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables Contraception 65 2002 215 221
27. S.O. Skouby, O. Andersen, and N. Saurberey Oral contraception and insulin sensitivity: in vivo assessment in normal women and women with previous gestational diabetes J Clin Endocrinol Metab 64 1987 519 523
28. F. Fruzzetti, C. Ricci, I. Nicoletti, and P. Fioretti Clinical and metabolic effects of a triphasic pill containing gestodene Contraception 46 1992 335 347
29. D. Cibula, G. Sindelka, M. Hill, M. Fanta, J. Skrha, and J. Zivny Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin Hum Reprod 17 2002 76 82
30. U.J. Gaspard, F. Demeyer, C.B. Jaminet, A.J. Scheen, and P.J. Lefebvre Influence of two low dose oral contraceptives containing ethinylestradiol (20 μg) and desogestrel or gestodene on carbohydrate metabolism during 1 year of use Gynecol Endocrinol 10 Suppl 1 1996 179 188
31. A. Cagnacci, S. Ferrari, A. Tirelli, R. Zanin, and A. Volpe Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial Contraception 79 2009 111 116
32. K.R. Petersen, E. Christiansen, S. Madsbad, S.O. Skouby, L.F. Andersen, and J. Jespersen Metabolic and fibrinolytic response to changed insulin sensitivity in users of oral contraceptives Contraception 60 1999 337 344
33. A. Cagnacci, A.M. Paoletti, A. Renzi, M. Orr, M. Pilloni, and G.B. Melis Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptive containing cyproterone acetate or desogestrel J Clin Endocrinol Metab 88 2003 3621 3625
34. J.C. Cohen, and R. Hickman Insulin resistance and decreased tolerance in powerlifters ingesting anabolic steroids J Clin Endocrinol Metab 64 1987 960 963
35. D.B. Corry, and M. Tuck The effect of aldosterone on glucose metabolism Curr Hypertens Rep 5 2003 106 109
36. D. Kraus, J. Jager, B. Meier, M. Fasshauer, and J. Klein Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes Horm Metab Res 37 2005 455 459
37. E. Dahlgren, K. Landin, M. Krotkiewski, G. Holm, and P.O. Janson Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome Hum Reprod 13 1998 2706 2711
38. L. Morin-Papunen, I. Vauhkonen, R.M. Koivunen, A. Ruokonen, H.K. Martikainen, and J.S. Tapanainen Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study J Clin Endocrinol Metab 85 2000 3161 3168